✨ Free AI Report
Pliant Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Pliant Therapeutics, Inc.
Company Research

Pliant Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Pliant Therapeutics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Turnaround opportunity dependent on oncology program success, but faces execution risk and cash runway constraints. While Pliant possesses strong scientific fundamentals and promising oncology data, the discontinuation of its lead IPF program represents a major setback. The company trades significantly below cash value, signaling market skepticism despite a diversified.

What is Pliant Therapeutics, Inc.'s industry? Pliant Therapeutics, Inc. (pliantrx.com) operates in Clinical-Stage Biopharmaceuticals / Specialty Therapeutics. AskCyborg classifies Pliant Therapeutics, Inc. under Clinical-Stage Biopharmaceuticals / Specialty Therapeutics in its company registry.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel integrin-based therapies for fibrotic diseases and solid tumors. The company leverages its expertise in int...

4/ 10Mixed

Cyborg Score thesis

Turnaround opportunity dependent on oncology program success, but faces execution risk and cash runway...

Read the full analyst-debate transcript →
Industry Clinical-Stage Biopharmaceuticals / Specialty Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Pliant Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Pliant Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Pliant Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Pliant Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Pliant Therapeutics, Inc. Overview

Pro stress-test →

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel integrin-based therapies for fibrotic diseases and solid tumors. The company leverages its expertise in integrin biology and TGF-β modulation to address serious conditions including idiopathic pulmonary fibrosis, primary sclerosing cholangitis, and liver fibrosis associated with NASH.

Strategic Profile

Pro stress-test →

Pliant pivoted away from its lead IPF program (bexotegrast) following disappointing Phase 2b trial results in March 2025, redirecting focus toward its oncology program with PLN-101095 showing promising antitumor activity. The company maintains a portfolio approach with multiple clinical-stage programs targeting different integrin pathways and therapeutic areas, demonstrating scientific depth in integrin modulation.

Competitive Landscape

Pro stress-test →

Pliant competes in antifibrotic therapeutics against companies like Boehringer Ingelheim, Roche (Galapagos assets), and FibroGen, while the oncology pivot positions it against immuno-oncology specialists. The company differentiates through its integrin-focused platform approach, though the failure of bexotegrast dilutes confidence in the fibrotic disease strategy and forces reliance on early-stage oncology success.

Industry Context

Pliant Therapeutics, Inc. operates in Clinical-Stage Biopharmaceuticals / Specialty Therapeutics.

Key facts

Founded: 2015 · Headquarters: South San Francisco, California · Market cap: $71M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Pliant Therapeutics, Inc..

  • Discontinued lead IPF program (bexotegrast/BEACON-IPF) in March 2025 after Phase 2b data did not meet endpoints, triggering stock decline and strategic pivot to oncology focus
  • PLN-101095 oncology candidate demonstrating 50% confirmed partial response rate in solid tumors across multiple types at highest dose tested, with additional data expected through end of 2025
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2025Discontinued BEACON-IPF Phase 2b trial following independent data safety monitoring board recommendation
  • June 2025Completed workforce and operational realignment to extend cash runway; discontinued bexotegrast in IPF
  • +1 moreTrack every material event for Pliant Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Pliant Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

NintedanibGold-standard anti-IPF tyrosine kinase inhibitor→PirfenidoneApproved therapy targeting TGF-β pathway for IPF→FibroGen oncology pipelineCompeting in fibrosis and related diseases→

Compare Pliant Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Pliant Therapeutics, Inc. operates in Clinical-Stage Biopharmaceuticals / Specialty Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical-Stage Biopharmaceuticals / Specialty Therapeutics research →
NEW · MCP server

Ask your AI assistant about Pliant Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Pliant Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Pliant Therapeutics, Inc. do this quarter?”
“Is Pliant Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Pliant Therapeutics, Inc. do?+
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel integrin-based therapies for fibrotic diseases and solid tumors. The company leverages its expertise in int...
What is Pliant Therapeutics, Inc.'s Cyborg Score?+
Pliant Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Pliant Therapeutics, Inc.'s main competitors?+
Named competitors include Nintedanib, Pirfenidone, FibroGen oncology pipeline. The full competitive landscape is in the AskCyborg report.
How can I get the full Pliant Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Pliant Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Pliant Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Clinical-Stage Biopharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7AtaiBeckley Inc.7NervGen Pharma Corp7Trevi Therapeutics, Inc.6Disc Medicine, Inc.6Sagimet Biosciences Inc.4OnKure Therapeutics, Inc.3Applied Therapeutics, Inc.